Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (1956)	3/6/2008 9:54:37 AM
From: richardred	Respond to of 7259

Analogic to Buy Copley Controls for $69M Thursday March 6, 8:38 am ET Analogic to Buy Copley Controls for $68.8M, Expects Purchase to Add to Adjusted 2008 Earnings PEABODY, Mass. (AP) -- Medical and security imaging equipment maker Analogic Corp. said Thursday it agreed to acquire Copley Controls Corp., which makes parts for MRI machines, for about $68.8 million in cash. Analogic also will pay up to $1.8 million to reimburse Copley shareholders for acquisition-related taxes. Analogic expects the acquisition to add to earnings beginning in the current fiscal year ending in July, excluding one-time acquisition costs. The company expects to gain over $85 million in revenue from the acquisition this year, compared with Copley's preliminary 2007 revenues of about $83 million. Chief Executive Jim Green said the purchase will expand product offerings and add business from Asia. Canton, Mass.-based Copley makes gradient amplifiers for MRI and precision motion control systems. Analogic expects the deal to close in early April. The company will fund the purchase through available cash. biz.yahoo.com

To: richardred who wrote (1956)	3/8/2008 12:39:02 PM
From: richardred	Read Replies (1) \| Respond to of 7259

Cardinal Buyout Adds Value, But Payoff Will Take Time Friday March 7, 5:56 pm ET Vance Cariaga When you're a $90 billion company, a $490 million buyout doesn't tend to move the needle much on Wall Street. Such was the case last week for Cardinal Health (NYSE:CAH - News), the nation's second-biggest distributor of drugs and medical products by annual sales. On Tuesday Cardinal announced plans to acquire privately held Enturia for $490 million. The deal, expected to close within a couple of months, brings Cardinal the ChloraPrep line of infection prevention products. ChloraPrep will be added to Cardinal's medical products and technologies segment. Cardinal Health expects the deal to reduce earnings this year before boosting the bottom line in 2009. Rising Demand Though the deal didn't have much positive impact on Cardinal's stock price -- shares actually fell last week -- most analysts offered an upbeat assessment of the buyout. "The acquisition is consistent with Cardinal's capital deployment strategy, and we view it favorably in light of current attention surrounding infection prevent products," analyst Eric Coldwell wrote in a report for Robert W. Baird & Co. Citigroup analyst Charles Boorady noted that the deal complements Cardinal's infection prevention strategy -- a niche he singled out as a growth driver in a recent upgrade of the company. Boorady says hospitals are willing to invest in infection prevention products because of changes in how Medicare and managed care firms reimburse treatment of some preventable infections. Beginning in October, the Centers for Medicare and Medicaid Services will no longer reimburse hospitals for the additional cost of treating certain infections acquired during hospital stays. "(This) puts new financial pressure on hospitals to reduce infections," Boorady said. "The cost of products like Enturia's ChloraPrep are in the single-digit dollar area per use, a small relative price to pay to cut expensive and risky infections." In a press release, Cardinal said ChloraPrep products are widely used in U.S. hospitals and surgery centers to disinfect the skin before surgical and vascular procedures. That helps prevent blood stream and surgical site infections -- two of the most common types of health-care-associated infections (HAI) among patients. "The technology is well-aligned with our mission to improve patient safety," Cardinal Chief Executive R. Kerry Clark said in a statement. "This is another good example of a tuck-in acquisition that complements our clinical and medical products sector and advances our strategy to help health care providers reduce HAIs." Analyst Coldwell pointed out that in studies comparing ChloraPrep with traditional iodine antiseptic, ChloraPrep "killed microorganisms more rapidly and more persistently, helping prevent cross-contamination." Cardinal plans to accelerate sales of ChloraPrep products to both hospital and alternate-care customers through its own U.S. and international sales networks. Street Gives A Cold Shoulder Management will have to do a lot of accelerating if the new unit is to have much impact on the top line. Cardinal is expected to post about $93 billion in revenue this fiscal year, which ends in June. Enturia's 2007 revenue was about $140 million, analysts estimate. "We don't expect a significant impact on Cardinal's overall performance," Coldwell wrote. That's one reason Wall Street reacted with a shrug to the news. Cardinal shares fell 1% on the day the Enturia deal was announced and continued to sell off most of the rest of the week. The stock traded near 56 early Friday, down 9% from its closing price on Feb. 26 and about 27% off a 52-week high set in late April. Cardinal's sell-off has followed a general industry decline. The 10 stocks in IBD's wholesale drugs and supplies distributors group are down 12% since mid-January and hit a five-and-a-half month low on Friday. Steep recent declines also have been reported by Cardinal's other two "Big Three" industry competitors, McKesson (NYSE:MCK - News) and AmerisourceBergen (NYSE:ABC - News). On the bright side, all three firms are expected to post double-digit earnings gains in three of the next four quarters. Coldwell sees a few favorable trends for the sector, including improving drug pipelines and stable pricing. "(The Big Three) are relatively insulated from many macroeconomic perils (while) also being less exposed to many consumer-specific (and other) risks present for many other health care entities," Coldwell wrote. biz.yahoo.com